The research into polylaminin, which has garnered attention after reports of improvements in patients with spinal cord injuries, faced rejection from scientific journals due to significant issues raised during the evaluation process. Reviewers highlighted two primary concerns: disagreements regarding the recovery rate of patients used as a reference in the study and the absence of prior registration of the clinical trial in a recognized international research database. As a result, the study, which was released as a pre-print (a preliminary version of a scientific article that has not yet undergone formal peer review), has not been accepted for publication by any journal as of now.

In an interview, the lead researcher, Tatiana Sampaio, acknowledged the shortcomings in the study and emphasized the importance of addressing the criticisms received during the submission process. She indicated that the research team plans to revise the article significantly, aiming to correct the identified errors and clarify the points of concern raised by editors and experts. This revision is crucial not only for improving the scientific rigor of the research but also for restoring credibility with the scientific community.

The implications of this ongoing research are significant, especially considering the potential benefits for patients with spinal cord injuries. Should the revised version adequately address the highlighted issues, it may pave the way for future publication and further research that could ultimately contribute to advancements in treatment options. However, until the study is successfully published and accepted by peer-reviewed journals, its scientific validity and impact remain questionable, making the next steps critical to the research's future development.